Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello, everyone. Damian here with an update on an erstwhile unicorn, the latest twist in the NASH saga, and the next regulatory debate over ALS.
A former unicorn is stumbling
Sana Biotechnology, a company that raised more than $1 billion to develop a suite of breakthrough medicines, is laying off about a third of its workforce and setting aside one of its most ambitious projects.
About the Author Reprints
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.